JAVELIN Bladder Medley
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
- NCT05327530 ↗
- Active, not recruiting
- EMD Serono Research & Development Institute, Inc.
- Deep
We haven't built an HCP commentary report on JAVELIN Bladder Medley (avelumab, sacituzumab govitecan and 3 more in Locally Advanced or Metastatic Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on JAVELIN Bladder Medley so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 20 | |
| YouTube | 3 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma
- Interventions
- Avelumab; Sacituzumab Govitecan (SG); M6223; NKTR-255; JB100
- Arms
- Avelumab · Experimental
- Avelumab + Sacituzumab Govitecan (SG) · Experimental
- Avelumab + M6223 · Experimental
- Group D: Avelumab + NKTR-255 · Experimental
- JB100 (NCT02603432) · Other
- Enrollment
- 256
- Primary outcomes
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + Sacituzumab Govitecan Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + M6223 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + NKTR-255 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events, and AEs of Special Interest (AESIs)
- Sponsor
- EMD Serono Research & Development Institute, Inc. with Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
- Start
- Aug 17, 2022
- Primary completion
- Jun 20, 2025
- Results posted
- Yes
- Registry record
- NCT05327530 · updated Sep 28, 2026
Publications
linked from the registry- Naing A, McKean M, Tolcher A, Victor A, Hu P, Gao W, Nogueira Filho MAF, Kitzing T, Gleicher S, Holland D, Richter E, Tadjalli-Mehr K, Siu LL. TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial. J Immunother Cancer. 2025 Feb 10;13(2):e010584. doi: 10.1136/jitc-2024-010584. PubMed 39929671
- Hoffman-Censits J, Grivas P, Powles T, Hawley J, Tyroller K, Seeberger S, Guenther S, Jacob N, Mehr KT, Hahn NM. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. Future Oncol. 2024 Feb;20(4):179-190. doi: 10.2217/fon-2023-0492. Epub 2023 Sep 6. PubMed 37671748